4,7,10,13,16,19-docosahexaenoic acid ethyl ester

RN given refers to compound with specified unsaturation and no isomeric designation

Also Known As:

(all-Z)-isomer, no locants for unsaturation of 4,7,10,13,16,19-docosahexaenoic acid ethyl ester; 4,7,10,13,16,19-docosahexaenoic acid ethyl ester, (all-Z)-isomer; DH-ethyl ester; docosahexaenoic acid ethyl ester

Networked: 10 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Lipids: 114793

Experts

1.	Kudou, Kentarou: 2 articles (11/2013 - 05/2013)
2.	Ootake, Jun: 2 articles (11/2013 - 05/2013)
3.	Saito, Yasushi: 2 articles (11/2013 - 05/2013)
4.	Tatsuno, Ichiro: 2 articles (11/2013 - 05/2013)
5.	Al Rijjal, Dana: 1 article (08/2021)
6.	Dai, Feihan F: 1 article (08/2021)
7.	Danaei, Zahra: 1 article (08/2021)
8.	Lai, Mi: 1 article (08/2021)
9.	Liu, Ying: 1 article (08/2021)
10.	Mohan, Haneesha: 1 article (08/2021)

Related Diseases

1.	Peroxisomal Disorders (Peroxisomal Disorder) 04/01/2010 - "Visual follow-up in peroxisomal-disorder patients treated with docosahexaenoic Acid ethyl ester." 07/01/1998 - "MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders." 01/01/2000 - "Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders."
2.	Hypertriglyceridemia 05/01/2013 - "We investigated the TG-lowering effects of TAK-085 (EPA-E + docosahexaenoic acid-ethyl ester) in comparison with EPA-E in Japanese patients with hypertriglyceridemia (TG ≥150 mg/dL and <750 mg/dL). " 11/01/2013 - "TAK-085 is an omega-3 preparation that contains eicosapentaenoic acid ethyl-ester (EPA-E) and docosahexaenoic acid-ethyl ester used in the management of hypertriglyceridemia. " 08/20/2021 - "Omega-3 fatty acid prescription drugs, Vascepa (≥96% eicosapentaenoic acid [EPA] ethyl ester) and Lovaza (46.5% EPA and 37.5% docosahexaenoic acid ethyl ester) are known therapeutic regimens to treat hypertriglyceridemia. "
3.	Psoriatic Arthritis 01/01/1990 - "A total of 80 patients with chronic, stable psoriasis, 34 of whom also had psoriatic arthritis, were treated with 1122 mg/day eicosapentaenoic acid ethyl ester and 756 mg/day docosahexaenoic acid ethyl ester. "
4.	Zellweger Syndrome (Zellweger's Syndrome) 03/01/1996 - "A patient with classic Zellweger syndrome was treated with docosahexaenoic acid ethyl ester (DHA-EE) for three months. "
5.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/1990 - "A total of 80 patients with chronic, stable psoriasis, 34 of whom also had psoriatic arthritis, were treated with 1122 mg/day eicosapentaenoic acid ethyl ester and 756 mg/day docosahexaenoic acid ethyl ester. "

Related Drugs and Biologics

1.	eicosapentaenoic acid ethyl ester
2.	Fatty Acids (Saturated Fatty Acids)
3.	TAK-085
4.	Prescription Drugs
5.	Therapeutic Uses
6.	Omega-3 Fatty Acids (Omega 3 Fatty Acids)
7.	Eicosapentaenoic Acid
8.	Lipids
9.	Heparin (Liquaemin)
10.	Nonesterified Fatty Acids (NEFA)